Venetoclax-obinutuzumab therapy shows sustained PFS and OS benefits over chemoimmunotherapy in untreated CLL patients with coexisting conditions. The CLL14 trial's 6-year follow-up confirms >50% of ...
Use of the 2024-2025 COVID-19 vaccine that targets the Omicron strain was associated with significantly fewer emergency department/urgent care (ED/UC) visits than no vaccination, especially in older ...
MANCHESTER, England — Febuxostat (Uloric) did not appear to increase the risk for major adverse cardiovascular (CV) events (MACEs) when compared with no urate-lowering therapy (ULT) in people with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback